Usefulness of microalbuminuria in the metabolic syndrome as a predictor of cardiovascular disease. Prospective study about 78 cases;Intérêt de la microalbuminurie au sein du syndrome métabolique dans la prédiction des évènements cardiovasculaires. Étude prospective à propos de 78 cas

Annales de Cardiologie et d'Angeiologie

Volumn 61, Issue 1, 2012, Pages 15-19

  Bendriss, L ^a   Lebbaq, A ^a   Jallal, H ^a   Mrani, S ^a   Khatouri, A ^a  

^a Cardiology clinic of military hospital   (Morocco)

Author keywords

Cardiovascular disease; Metabolic syndrome; Microalbuminuria

Indexed keywords

ALBUMIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MICROALBUMINURIA; MOROCCO; PREDICTION; PREVALENCE; PROSPECTIVE STUDY; PUBLIC HOSPITAL; RISK ASSESSMENT; SAMPLE SIZE;

ALBUMINURIA; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84857064046     PISSN: 00033928     EISSN: 17683181     Source Type: Journal    
DOI: 10.1016/j.ancard.2011.04.011     Document Type: Article

References (32)

1. National Kidney Foundation KDOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S46-S76.
2. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984, 310:356-360.
3. Ljungman S., Wikstrand J., HartfordM, Berglund G. Urinary albumin excretion - a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged non diabetic normal and hypertensive men. Am J Hypertens 1996, 9:770-778.
4. Arnlov J., Evans J.C., Meigs J.B., et al. Low-grade albuminuria and incidence of cardiovascular disease events in non hypertensive and non diabetic individuals: the Framingham Heart Study. Circulation 2005, 112:969-975.
5. Laaksonen D.E., Lakka H.M., Niskanen L.K., Kaplan G.A., et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002, 156:1070-1077.
6. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
7. Gale E.A. The myth of the metabolic syndrome. Diabetologia 2005, 48:1679-1683.
8. Kahn R. Metabolic syndrome: is it a syndrome? Does it matter?. Circulation 2007, 115:1806-1811.
9. Chen J., Muntner P., Hamm L.L., et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004, 140:167-174.
10. Hao Z., Konta T., Takasaki S., et al. The association between microalbuminuria and metabolic syndrome in the general population in Japan: The Takahata Study. Inter Med 2006, 46(7):341-346.
11. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
12. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005, 366:1059-1062.
13. Klausen K.P., Parving H.H., et al. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. J Intern Med 2007, 262(4):470-478.
14. Palaniappan L., Carnethon M., Fortmann S.P. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003, 16:952-958.
15. Jassal K.S., Langenberg C., et al. Usefulness of microalbuminuria versus the metabolic syndrome as a predictor of cardiovascular disease in women and men >40 years of age (from the Rancho Bernardo Study). Am J Cardiol 2008, 101(9):1275-1280.
16. Valmadrid C.T., Klein R., Moss S.E., Klein B.E. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000, 160:1093-1100.
17. Wachtell K., Ibsen H., Olsen M.H., Borch-Johnsen K., et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003, 139:901-906.
18. Ravera M., Ratto E., Vettoretti S., Viazzi F., et al. Microalbuminuria and subclinical cerebrovascular damage in essential hypertension. J Nephrol 2002, 15:519-524.
19. Diercks G.F., van Boven A.J., Hillege H.L., Janssen W.M., et al. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The Prevend (Prevention of REnal and Vascular ENdstage Disease) study. Eur Heart J 2000, 21:1922-1927.
20. Zandbergen A.A., Sijbrands E.J., Lamberts S.W., Bootsma A.H. Normotensive women with type 2 diabetes and microalbuminuria are at high risk for macrovascular disease. Diabetes Care 2006, 29:1851-1855.
21. Bonora E., Targher G., Formentini G., Calcaterra F., et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004, 21:52-58.
22. Howard B.V., Best L.G., Galloway J.M., Howard W.J., et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 2006, 29:391-397.
23. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Al S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421-426.
24. Wachtell K., Palmieri V., Olsen M.H., Bella J.N., et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan intervention for endpoint reduction. Am Heart J 2002, 143:319-326.
25. Yuyun M.F., Khaw K.T., Luben R., Welch A., et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol 2004, 159:284-293.
26. Weiner D.E., Sarnak M.J. Microalbuminuria: a marker of cardiovascular risk. Am J Kidney Dis 2003, 42:596-598.
27. Bruno G., Merletti F., Biggeri A., Bargero G., et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes. Diabetes Care 2004, 27:2689-2694.
28. Gimeno-Orna J.A., Herguedas E.M., Luis M., Arnal L., et al. Microalbuminuria accounts for the increased vascular disease risk in diabetic patients with metabolic syndrome. Rev Esp Cardiol 2007, 60(11):1202-1205.
29. Gimeno Orna J.A., Lou-Arnal L.M., Molinero-Herguedas E., Boned Juliani B. Syndrome metabolico como marcador de riesgo cardiovascular en pacientes con diabetes tipo 2. Rev Esp Cardiol 2004, 57:507-513.
30. Stehouwer C.D., Nauta J.J., Zeldenrust G.C., Hackeng W.H., et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992, 340:319-323.
31. Balkau B., Charles M.A. Comment on the provisional report from the WHO consultation. Diabet Med 1999, 16:442-443. European Group for the Study of Insulin Resistance (EGIR).
32. Solbu M.D., Kronborg J., Jenssen T.G., Njolstad I., et al. Albuminuria, metabolic syndrome and the risk of mortality and cardiovascular events. Atherosclerosis 2009, 204:503-508.